Storyline
BMS advances next-gen myeloma drug mezigdomide after positive phase 3 results
Bristol Myers Squibb (BMS) reported successful phase 3 trial results for mezigdomide, a next-generation cereblon modulator (celmod) targeting multiple myeloma.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- pharmaphorumpharmaphorum.com
- BioPharma Divebiopharmadive.com